Provided by Tiger Trade Technology Pte. Ltd.

Ionis Pharmaceuticals

81.15
+0.55000.68%
Post-market: 81.150.00000.00%19:53 EST
Volume:2.77M
Turnover:225.26M
Market Cap:13.41B
PE:-34.10
High:82.10
Open:80.59
Low:80.06
Close:80.60
52wk High:86.74
52wk Low:23.95
Shares:165.19M
Float Shares:164.00M
Volume Ratio:1.03
T/O Rate:1.69%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3800
EPS(LYR):-2.3812
ROE:-70.73%
ROA:-7.32%
PB:27.41
PE(LYR):-34.08

Loading ...

Earnings Flash (IONS) Ionis Pharmaceuticals Posts Q4 Revenue $203M, vs. FactSet Est of $157.7M

MT Newswires Live
·
Feb 25

Ionis Q4 revenue USD 203 million, up 64% on commercial revenue

Reuters
·
Feb 25

Ionis Pharmaceuticals Q4 Adj. EPS $(1.15) Beats $(1.32) Estimate, Sales $203.000M Beat $156.094M Estimate

Benzinga
·
Feb 25

BRIEF-Ionis Pharmaceuticals Q4 Revenue USD 203 Million Vs. IBES Estimate USD 156.1 Million

Reuters
·
Feb 25

Ionis Pharmaceuticals Q4 Adjusted Operating Expenses USD 375 Million

THOMSON REUTERS
·
Feb 25

Ionis Pharmaceuticals Inc: Outlook 2026 Revenue $800- $825 Mln

THOMSON REUTERS
·
Feb 25

Ionis Pharmaceuticals Q4 Operating Income USD -215 Million

THOMSON REUTERS
·
Feb 25

Ionis Pharmaceuticals Q4 Operating Expenses USD 418 Million

THOMSON REUTERS
·
Feb 25

U.S. Earnings Preview: Before Market Open Feb. 25

Dow Jones
·
Feb 25

Ionis Pharmaceuticals to Present at Upcoming Investor Conferences

Reuters
·
Feb 19

A Look At Ionis Pharmaceuticals (IONS) Valuation After Recent Share Price Strength And Mixed Analyst Signals

Simply Wall St.
·
Feb 19

Earning Preview: Ionis Pharmaceuticals this quarter’s revenue is expected to increase by 13.44%, and institutional views are bullish

Earnings Agent
·
Feb 18

Ionis Pharmaceuticals Inc. updates time for financial results webcast

Reuters
·
Feb 18

Ionis Updates Time for Fourth Quarter and Full Year 2025 Financial Results Webcast

THOMSON REUTERS
·
Feb 18

Director Lynne Parshall Reports Sale of Ionis Pharmaceuticals Common Shares

Reuters
·
Feb 14

Press Release: Ionis to hold fourth quarter and full year 2025 financial results webcast

Dow Jones
·
Feb 11

Ionis Pharmaceuticals CEO Brett P. Monia Reports Sale of Common Shares

Reuters
·
Feb 11

Ionis Pharmaceuticals (IONS) Valuation Check As Dawnzera Approval And Other Milestones Support Growth Prospects

Simply Wall St.
·
Feb 08

Ionis Pharmaceuticals Is Maintained at Overweight by Piper Sandler

Dow Jones
·
Feb 07

Ionis Pharmaceuticals price target raised to $87 from $77 at Piper Sandler

TIPRANKS
·
Feb 06